Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original empirical data
PubMed 34665436 · doi:10.1007/s12282-021-01298-x
What was done
This narrative review summarizes clinical approaches to breast cancer risk assessment, covering genetic and reproductive risk factors, mammographic breast density, risk-prediction models, risk-reducing medications, lifestyle modifications, and supplemental screening modalities.
What was found
The abstract reports that breast cancer affects 1 in 8 women in the United States (12.5% lifetime risk) as baseline context, but it reports no primary numerical data, statistical comparisons, or quantitative outcomes from the review itself.
Why it matters
It highlights the clinical necessity of moving from uniform age-based screening to individualized risk assessment to identify women who benefit from intensified surveillance or chemoprevention.
Limits
As a narrative review, it lacks a systematic literature search, formal inclusion or exclusion criteria, and quality assessment of reviewed evidence. No original data or meta-analytic estimates are presented in the abstract.
Cited by
- supports The average lifetime risk of developing breast cancer for an American woman is approximately 12.5%.